BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
UBS
Cipla
Baxter
Chubb
Argus Health
Healthtrust
Novartis
QuintilesIMS
Medtronic

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,799,771

« Back to Dashboard

Which drugs does patent 7,799,771 protect, and when does it expire?

Patent 7,799,771 protects FEMTRACE and is included in one NDA.

This patent has eleven patent family members in ten countries.
Summary for Patent: 7,799,771
Title:Oral pharmaceutical products containing 17.beta.-estradiol-3-lower alkanoate, method of administering the same and process of preparation
Abstract:A pharmaceutical dosage unit for oral administration to a human female comprising a therapeutically effective amount of 17.beta.-estradiol-3-lower alkanoate, most preferably 17.beta.-estradiol-3-acetate, and a pharmaceutically acceptable carrier is disclosed. Also disclosed is a method for treating a human female in need of 17.beta.-estradiol and a contraceptive method by oral administration of the pharmaceutical dosage unit and a method of preparing a pharmaceutical composition that may be used to form the pharmaceutical dosage unit of the invention.
Inventor(s): Aloba; Oluwole T. (Morristown, NJ), deVries; Tina M. (Long Valley, NJ)
Assignee: Warner Chilcott Company, LLC. (Fajardo, PR)
Application Number:11/154,704
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Formulation;

Drugs Protected by US Patent 7,799,771

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Apil FEMTRACE estradiol acetate TABLET;ORAL 021633-001 Aug 20, 2004 DISCN Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Apil FEMTRACE estradiol acetate TABLET;ORAL 021633-002 Aug 20, 2004 DISCN Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Apil FEMTRACE estradiol acetate TABLET;ORAL 021633-003 Aug 20, 2004 DISCN Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,799,771

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,962,908 Oral pharmaceutical products containing 17 .beta.-estradiol-3-lower alkanoate, method of administering the same and process of preparation ➤ Subscribe
7,572,779 Oral pharmaceutical products containing 17.beta.-estradiol-3-lower alkanoate, method of administering the same and process of preparation ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,799,771

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2470703 ➤ Subscribe
China 1564689 ➤ Subscribe
China 1273141 ➤ Subscribe
European Patent Office 1461043 ➤ Subscribe
Israel 160797 ➤ Subscribe
Japan 2005517673 ➤ Subscribe
Mexico PA04006057 ➤ Subscribe
Norway 20042565 ➤ Subscribe
New Zealand 532491 ➤ Subscribe
Australia 2002359758 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
US Army
McKinsey
Argus Health
Daiichi Sankyo
Boehringer Ingelheim
Fuji
US Department of Justice
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot